Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06048185 · ClinicalTrials.gov registry record
Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study
A clinical trial of Stargardt Disease, sponsored by Nanoscope Therapeutics.
- Active
- Registry status
- 6
- Enrollment target
- 2
- Study locations
NCT06048185 is a study of Stargardt Disease that is active but no longer recruiting, run by Nanoscope Therapeutics. The registered enrollment target is 6 participants, below the 91-participant average among 16 other Stargardt Disease trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06048185, a study of Stargardt Disease, is active but no longer recruiting, sponsored by Nanoscope Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- 6 participants
- Enrollment target
- 2
- Study locations
Study Summary
The current study is a non-interventional long-term safety follow-up of the subjects who completed STARLIGHT, in accordance with FDA guidance on recipients of human gene therapy products.
Conditions Studied
Interventions
- BIOLOGICAL Gene Therapy Product-MCO-010
Study Locations (2)
Florida
- Nanocope Clnical Site - Miami
Texas
- Nanoscope Clinical Site - McAllen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2023-10-19 |
| Est. Completion | 2027-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06048185
The ClinicalTrials.gov registry entry for NCT06048185 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 91-participant average among 16 other Stargardt Disease trials with a reported enrollment target (93% lower). The listed sponsor is Nanoscope Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stargardt Disease appearing as the primary indexed condition, and to 1 intervention - of which Gene Therapy Product-MCO-010 is the first listed.
NCT06048185 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT06048185 about?
NCT06048185 is a clinical study titled "Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study". The current study is a non-interventional long-term safety follow-up of the subjects who completed STARLIGHT, in accordance with FDA guidance on recipients of human gene therapy products.
What is the current status of trial NCT06048185?
This trial is currently active not recruiting. The enrollment target is 6 participants. The study started on 2023-10-19. Estimated completion is 2027-07.
What conditions does trial NCT06048185 study?
This clinical trial studies the following conditions: Stargardt Disease.
What interventions are being tested in trial NCT06048185?
The interventions under investigation include: Gene Therapy Product-MCO-010 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06048185?
This trial is sponsored by Nanoscope Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06048185 being conducted?
This trial has 2 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stargardt Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Observational Study in Children and Adults With Stargardt Disease
RECRUITING
-
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
RECRUITING · Phase 1
-
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
RECRUITING
-
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
RECRUITING
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
-
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.